Volitionrx Limited (VNRX) fundamentals score
Imagine a world where diseases like cancer and sepsis can be diagnosed early and monitored easily using routine blood tests. That’s the world Volition is trying to build by developing its innovative family of simple, easy to use, cost-effective blood tests.
In Vitro & In Vivo Diagnostic Substances · Healthcare · Listed on NYSE
Overall: 4.8 out of 10, Weak long-term fundamentals
- Growth: 4.3/10
- Profitability: 4.0/10
- Financial health: 1.9/10
- Earnings quality: 8.8/10
- Valuation: 7.0/10
Scores are calculated from Volitionrx Limited’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10